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Objective: To assess the long-term performance of the bifurcated Zenith stent graft.
Methods: A total of 325 patients (300 men and 25 women) underwent elective endovascular abdominal aortic aneurysm
repair with bifurcated Zenith stent grafts between October 1998 and December 2005. Follow-up included routine
contrast-enhanced computed tomography and multiview abdominal radiographs at 1, 6, and 12 months and yearly
thereafter. Data on late-occurring (>30 days after stent-graft implantation) complications and interventions were
collected prospectively.
Results:Of the original 325 patients, 92 have since died, resulting in a mean follow-up of 2.3 years (range, 1 month to 7.0
years). Nine (2.8%) of 325 patients required reintervention to treat or prevent endoleak (type I or III) or graft occlusion
at an average of 1.4 years after stent-graft placement (range, 40 days to 4.0 years). Three (0.9%) of these patients died
from causes related tomalfunction of the stent graft: one each from aneurysm rupture, stent-graft infection, and infection
of a femoral-femoral bypass graft placed after limb occlusion. Nineteen additional patients (5.8%) required treatment for
type II endoleak, for a total reintervention rate of 8.6%.
Conclusions: Late failures of Zenith stent-graft attachment, structure, or function are rare. In the absence of known
endoleak, routine follow-up imaging plays a limited role in the identification and prevention of impending failure.
(J Vasc Surg 2007;45:461-6.)Endovascular abdominal aortic aneurysm (AAA) repair
depends on the presence of an intraluminal stent graft to
exclude the aneurysm from arterial flow and pressure,
thereby preventing aneurysm dilatation and rupture while
maintaining flow to distal organs. Although the ultimate
goal may be the prevention of aneurysm rupture, endovas-
cular aneurysm repair can also be considered a failure when
blood flows outside the confines of the stent graft (en-
doleak), the graft occludes, or additional interventions are
necessary.
Stent grafts differ in their ability to traverse the iliac
arteries and gain hemostatic implantation above and below
the aneurysm. They differ even more in their ability to
withstand the cyclical stresses and strains imposed by he-
modynamic forces.1-3 Stent-graft materials, shapes, and
attachment mechanisms vary widely, as do the long-term
results of endovascular aneurysm repair. Large prospective
studies4-6 and registries1 have failed to produce the kind of
device-specific data on the long-term functional outcome
of endovascular aneurysm repair that are needed for in-
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Predicate designs of the Zenith stent graft (Cook Inc,
Bloomington, Ind) were first implanted in 1994. We began
using the current device in 1998, and widespread use in the
United States followed Food and Drug Administration
approval in 2003. Long-term results have yet to be re-
ported. The initial industry-sponsored study required only
2 years of follow-up.7 Although the study period has since
been extended, the results have not been vetted, analyzed,
or published.
This single-center report focuses on the function of the
standard Zenith stent graft and the interventions necessary to
maintain stent-graft function. We have also attempted to
identify the timing, causes, and effects of failing stent-graft
function as a basis for future patient selection and follow-up.
METHODS
A total of 325 patients underwent elective endovascular
AAA repair by using bifurcated Zenith stent grafts between
October 1998 and December 2005 at the University of
California–San Francisco Medical Center. Data on late-
occurring (30 days after stent-graft implantation) com-
plications and interventions were collected prospectively.
Subjects were excluded from the analysis if the operation
was urgent or emergent or involved the implantation of
uni-iliac, fenestrated, or multibranched devices. Follow-up
included routine contrast-enhanced computed tomogra-
phy (CT) andmultiview abdominal radiographs at 1, 6, and
12 months and yearly thereafter. Exhaustive efforts to
identify all causes of death included interviewing the pa-
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obtaining all available death certificates.
Patient demographic information, including age, sex,
aneurysm size, medical comorbidities, and creatinine levels,
were collected prospectively. Before approval of the Zenith
stent graft in 2003, all patients were enrolled in a single-
center investigational device exemption protocol, for which
one of the selection criteria specified high-risk status. All
these high-risk patients had serious comorbid conditions.
Data on medical comorbidities included the presence of
diabetes mellitus, chronic obstructive pulmonary disease,
and cardiac disease. Cardiac disease included any history of
myocardial infarction, congestive heart failure, ischemic
heart disease, or atrial fibrillation.
Failure of stent-graft function included failure to ex-
clude the aneurysm from direct aortic flow (endoleak type I
or III) and failure to convey blood to the iliac arteries (graft
occlusion). Impending failure of stent-graft function in-
cluded component separation (without endoleak) and
kinking of the stent graft (without thrombosis). In terms of
clinical outcome, the distinction is unimportant; they all
resulted in reintervention. Those occurring more than 30
days after stent-graft implantation are combined here as
cases of late failure, although they might equally well be
termed late reintervention.
Cases of type II endoleak, and reintervention for type II
endoleak, were analyzed separately in the absence of its
contribution as a primary failure mode. Invasive treatment
for a type II endoleak consisted of coil embolization of
either the inferior mesenteric artery or the lumbar arteries.
The selection criteria for endovascular AAA repair, meth-
ods of device insertion, and follow-up protocol did not
change during the course of the study. However, the
indications for treatment of a type II endoleak did change.
Initially, the presence of any type II endoleak on the
1-month follow-up study was a sufficient indication for
reintervention. Over the last 3 years of the study, type II
endoleaks were treated only if the aneurysm size increased
on follow-up CT scans.
All statistical analyses were performed by using Stata
version 9.0 (StataCorp, College Station, Tex). Clinical
features of patients with late failure were compared with
those of the study cohort. Patients treated for a type II
endoleak were compared with patients who had an un-
treated type II endoleak. Measured values are reported as
percentages or means SD. The Student t test was used to
compare the means of continuous variables, and the Pear-
son 2 test and Fisher exact test were used to compare
categorical variables. P  .05 was considered statistically
significant. Overall survival, freedom from late graft failure,
and freedom from aneurysm-related mortality were calcu-
lated by using life-table analysis. The log-rank test was used
to compare the Kaplan-Meier estimate of freedom from
intervention for late failure.
RESULTS
The demographic features of the study cohort are dis-
played in Table I. Themean age in this cohort was 75.9 7.4years (range, 56.4-95.3 years), with 300 (92.3%) men and 25
(7.7%) women. Themean follow-up time was 836.4 580.2
days (range, 30-2547 days). Cumulative follow-up rates
were 37.2% (121 patients) at 3 years, 21.8% (71 patients) at
4 years, and 10.2% (33 patients) at 5 years. Overall, women
were older than men at the time of operation (77.6 years
compared with 75.7 years), but this was not statistically
significant (P  .23). A total of 92 (28.3%) of the 325
patients were dead at the time of this study, and 25 patients
(7.7%) were lost to follow-up.
There were a total of 9 (2.8%) instances of late failure,
comprising limb occlusion (n 2), aneurysm rupture (n
1), type III endoleak (n  3), limb kink without occlusion
(n  1), occlusion of a renal artery (n  1), and graft
infection (n  1). The average time after stent-graft place-
ment to late failure was 516.7 days (range, 40-1454 days).
Three deaths were attributed to late failure: one each of
aneurysm rupture, stent-graft infection, and infection of a
femoral-femoral bypass graft placed after limb occlusion.
Table II shows the clinical characteristics of patients
who experienced late failure compared with the study co-
hort. The preoperative creatinine level, medical comorbidi-
ties, aneurysm size, and length of follow-up were all similar
between the two groups. Those who experienced late fail-
ure were older at the time of AAA repair than those who did
not (79.9 vs 75.8 years), but this did not reach statistical
significance (P  .11). There was also a disproportionately
higher number of women who required reintervention, but
this also did not reach statistical significance (P  .15).
The unadjusted Kaplan-Meier estimates for freedom
from late failure are shown in Fig 1. Fig 1, a, shows the
overall freedom from late failure in the entire cohort.
Table I. Patient demographics of the cohort treated with
the Zenith stent graft
Variable Data
Age at operation (y)






Mean  SD 1.2  0.5
Range 0.6-7.1
Follow-up (d)
Mean  SD 836.4  580.2
Range 30-2547
Aneurysm size (mm)
Mean  SD 59.5  9.4
Range 32-100
Medical comorbidities
Diabetes mellitus 51 (17.0%)
Smoker 49 (16.0%)
Past smoker 210 (64.6%)
Cardiac disease 213 (66.4%)
COPD 102 (31.8%)
COPD, Chronic obstructive pulmonary disease.Women seem to have increased rates of late failure over
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However, this association is not statistically significant (P
.09 by log-rank test). Fig 2, a, shows the Kaplan-Meier
estimate of all-cause mortality, and Fig 2, b, shows overall
freedom from aneurysm-related mortality.
There were 74 patients (23%) in our study cohort with
a type II endoleak, of whom 19 underwent percutaneous
intervention. The clinical characteristics of patients with
treated and untreated type II endoleaks are shown in Table
III. The 19 treated cases represent 5.8% of the entire study
cohort. The overall intervention rate, including reinterven-
tion for late failure, is therefore 8.6% (28 patients).
DISCUSSION
All the cases of failure and impending failure of endo-
vascular AAA repair necessitated treatment. All limb occlu-
sions resulted in bypass or thrombolysis, followed by stent
insertion. All type III endoleaks resulted in the insertion of
additional stent-graft components. The same is not true of
type II endoleak, which was treated less aggressively as the
study progressed.
No patient in this study developed a type I endoleak or
underwent reintervention as a result of migration. The
absence of clinically relevant proximal attachment failure
probably reflects the effects of the barbed proximal stent of
the Zenith stent graft. Other stent-graft designs, which lack
barb-mediated proximal attachment, are subject to high
rates of migration,3 leading to secondary type I endoleak,
reintervention, and aneurysm rupture.8
The type III endoleaks occurred on average 660 days
after stent-graft insertion, thus indicating an unstable stent-
graft structure or position. The implantation technique
Table II. Patient characteristics of those requiring









Age at operation (y) .11
Mean  SD 79.9  5.3 75.8  7.5
Range 72.3-90.8 56.4-95.3
Sex .15
Male 7 (77.8%) 293 (92.7%)
Female 2 (22.2%) 23 (7.3%)
Creatinine (mg/dL) .64
Mean  SD 1.3  0.5 1.2  0.5
Range 0.7-2.1 0.6-7.1
Follow-up (d) .73
Mean  SD 903.7  592.0 834.5  580.7
Range 174-1682 30-2547
Aneurysm size (mm) .97
Mean  SD 59.3  6.9 59.5  9.4
Range 43-67 32-100
Medical comorbidities
Diabetes mellitus 2 (22.2%) 49 (16.8%) .65
Cardiac disease 3 (33.3%) 210 (67.3%) .07
COPD 3 (33.3%) 99 (31.7%) 1.0
COPD, Chronic obstructive pulmonary disease.seems to have played a role. During the course of the study,we increased the degree of intercomponent overlap to a
minimum of 1.5 stent body lengths, and none of the stent
grafts implanted in the past 5 years has developed either
component separation or type III endoleak.
Late graft occlusion occurred in 2 (0.6%) of 325
cases. Others studies have reported slightly higher
rates,1,2,6,9,10 and the Zenith stent graft has been noted
to perform worse in this regard than other contemporary
stent grafts. Our experience has shown that additional
stent support, in the form of a Wallstent (Boston Scien-
tific, Natick, Mass), is effective prophylaxis against graft
occlusion, but at-risk cases can be difficult to identify.11
Most of these Wallstents were inserted within a month of
stent-graft implantation, if not at the initial operation.
Only one patient underwent reintervention on the basis
of the finding of impending graft limb occlusion (kink-
ing) on routine follow-up imaging.
Large multicenter registries in Europe have shown
high rates of late failure, due largely to a high incidence
Fig 1. Kaplan-Meier estimate of freedom from late failure in
(A) the entire cohort and in (B) women compared with men (P
.09). The number of patients at each interval is shown at the
bottom of the graph.of stent fractures and graft erosion affecting one device,
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Natick, Mass).1 No currently used stent grafts are so
susceptible to structural degradation, but all are found to
have fractures or small holes when explanted or studied
with high-resolution imaging.12 The Zenith device is no
exception,13 and we have seen stent fracture, barb sepa-
ration, and top stent separation on routine plain abdom-
inal radiographs. However, none has ever affected stent-
graft function or led us to reintervene.
The unique feature of this study is the length of follow-
up. The first cases in this series were performed in late 1998.
The pivotal Zenith trial started in 2000, but only the 2-year
data have as yet been published.7 This article is based on
more than 3 years of follow-up in 121 patients (and more
than 5 years in 33 patients). We believe this to be a sound
basis for assessing long-term results.
The findings reported in this study led us to change
our routine follow-up protocol after endovascular AAA
repair. We still obtain CT scans but omit intravenous
contrast enhancement if the 1-month postoperative CT
scan demonstrates appropriate position and function and lack
Fig 2. Kaplan-Meier estimates of all-cause mortality (A) and
aneurysm-related mortality (B). The number of patients at each
interval is shown at the bottom of the graph.of an endoleak. All type II endoleaks in our study cohort weredetected on the 1-month postoperative CT scan. We believe
that the potential nephrotoxicity14 is not justified, given the
infrequent diagnosis of treatable problems such as secondary
endoleak (types I and III) and graft limb kinking. We still
perform noncontrast CT scans and plain abdominal radio-
graphs as routine follow-up to look for changes in aneurysm
diameter or changes in stent-graft structure. The yield may be
low, but neither test has any serious side effects.
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Dr William Quinones-Baldrich (Los Angeles, Calif): This is
a review of events occurring after 30 days of implantation of the
Zenith aortic endograft for the treatment of infrarenal abdominal
aortic aneurysms. The authors report an incidence of type II
endoleak of 5.8%, which is quite low, and no type I endoleaks.
Similarly, graft occlusions were rare, only one requiring surgical
treatment with a femorofemoral bypass. The authors also find that
hypertensive patients with type II endoleaks more often require
intervention for increase in the size of the aneurysm. The latter is
an important finding as it strongly suggests that in the presence of
a type II endoleak, blood pressure control is of benefit.
The authors also conclude that routine follow-up imaging
plays a limited role in the identification and prevention of graft
failure. They now recommend CT scan without contrast, noting
that the size of the aneurysm and detection of migration are the
most important factors during follow-up. Several reports are not-
ing a gradual decrease in renal function in patients treated with
endovascular grafts regardless of whether or not suprarenal fixation
is present. Therefore, avoiding contrast during follow-up in these
patients is important.
The occurrence of type III endoleaks leads the authors to
increase the degree of intercomponent overlap to a minimum of
1½ stents. Their experience with graft limb occlusion has led them
to be more aggressive in placing stents in areas of concern at the
time of implantation. These are excellent recommendations based
on the authors’ extensive experience with this device.
Unfortunately, this report only presents part of the picture. By
omitting events during the first 30 days of follow-up, the incidence
of postimplantation events is underestimated. In the manuscript, it
is clear that several type I endoleaks were treated with proximal
extensions, some limb occlusions were treated with thrombolysis
and stent placement, and some type III endoleaks were also
detected. They have also observed stent fractures, barb separation,
and top stent separation. The latter events are more likely to have
occurred after 30 days. I have several questions for the authors.
During follow-up you found that women tend to have more
events than men. My first question is why are there so few women
in your cohort? Does gender influence your recommendations?
Even though it is not the emphasis of your presentation today,
could you give us information on events occurring in the first 30
days? What is the overall incidence of type I, II, and III endoleaks
in your experience? When and how often were the stent fractures,
bar and/or stent separation observed? Do you have information on
long-term renal function in patients receiving the Zenith endograft
for treatment of their abdominal aortic aneurysms? And finally, inif everything looks well, I will then alternate duplex scan and CT
during the follow-up. Have you had any experience using duplex
scan for follow-up?
I congratulate the authors on an excellent experience and
thank you for providing me a copy of the manuscript in advance of
the meeting. I also wish to thank the society for the privilege of
discussing this paper.
Dr JadeHiramoto: Thank you, Dr Quinones. With regard to
your first question, we did not alter our recommendations for
treatment based on gender. We did have very few women in our
study. Part of this may be explained by the fact that a large
proportion of our operations were performed at the VA, where
essentially all of the patients are men. Gender may initially have
played a role in our recommendations when we were worried that
because of access issues they might not be appropriate candidates;
however, we use the same anatomic criteria for all patients. We do
not take gender into consideration now. We look at the diameters
of our access vessels andmake appropriate recommendations based
on those size measurements.
Women did tend to do worse in terms of late graft failure.
They were also more likely to require treatment for their type II
endoleaks, and if you actually look at all interventions—early
complications, late complications, treatment of type II en-
doleaks—it is statistically significant. It did not reach statistical
significance when you just looked at each of these separately, but if
you pooled all interventions they (women) did worse. I think it is
difficult to explain. The women tended to be older on presentation
for their aneurysm repair, but there did not appear to be an
interaction between age and gender. Gender itself was an indepen-
dent predictor.
Again, this talk was really devoted towards looking at the
long-term complications since this device has been in use since
1998 at UCSF, and we wanted to analyze and present our long-
term data. However, with regards to complications fromwithin the
first 30 days, there were a total of 10, for an overall late and early
complication rate of 19 in the entire cohort. The majority of the
early complications, as you might imagine, were limb thromboses.
It was probably 7 out of those 10. There were probably 1 or 2 type
I endoleaks and no treated type II endoleaks in the first 30 days.
With regards to stent fracture, barb fractures, and stent sepa-
ration, there has been a total of four in our series and they have not
required treatment. They have been recognized on the follow-up
abdominal x-rays and followed but not treated.
In terms of the long-term renal function of these patients, I do
not have all of their data analyzed at this point to determine the
number of patients who have had worsening renal function or
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our data. I do have their preoperative values, and there was quite a
range, but the average preoperative creatinine was 1.2. With re-
gards to duplex ultrasound, I think that it is an excellent imaging
modality. I think in the face of going to noncontrast CT scans if the
1-month postoperative contrast-enhanced CT does not demon-
strate enlargement of the aneurysm or an endoleak, I think a
duplex would be a great adjunctive measure to include. This would
be especially useful in a patient who maybe has some renal insuffi-
ciency, gets a noncontrast CT scan, and there is a question of
aneurysm sac enlargement; perhaps a duplex would be useful in
that patient to determine if they have evidence of an endoleak.
8. “Late Complications After Endovascular Aneurysm Repair
Using the Zenith Stent Graft.” Discussion by Benjamin Starnes,
Tacoma, WA.
DrBenjamin Starnes (Tacoma,Wash): I congratulate you on
a very impressive experience. One of the unique aspects, and in my
opinion, one of the favorable aspects of the Zenith system is that
however, postoperative imaging should clearly be performed. Thethe main body is sized all the way down to the aortic bifurcation
and this theoretically assists in preventing distal migration. You had
one case where the renal artery was occluded, you presumed,
because of overlap of the orifice of the renal artery. I am wonder-
ing, because I have had one similar case, have you ever seen any
instance of proximal migration of the graft after aneurysm remod-
eling, especially in very large aortic aneurysms?
DrHiramoto:Not tomy knowledge, and certainly not in this
series of patients. This one case of renal artery occlusion that we
presented today was clearly an intraoperative event that was not
recognized at the time of the procedure. Looking back at the
intraoperative angiogram, you see that the top of the covered
portion of the stent graft was almost completely covering that renal
artery. This was the only patient in which that occurred, and again,
I think this was an early mistake that was recognized late. This was
not a case of proximal migration, nor have we observed proximal
migration in this series of patients.INVITED COMMENTARYMark F. Fillinger, MD, Lebanon, NH
I enjoyed reading this article, which is important because of its
size and length of follow-up (at least 3 years in 121 of 325
patients). The clinical results are excellent, with a low rate of
reintervention and aneurysm-related death beyond 30 days. That
being said, the follow-up is primarily from 30 days to 5 years,
defined as “mid-term” by Society for Vascular Surgery reporting
standards,1 and should be taken in that context.
I was initially taken aback when I read that “Large prospec-
tive studies and registries have failed to produce the kind of
device specific data. . .needed for informed decisions on patient
selection, device selection, and follow-up.” I suspect the authors
of the DREAM, EVAR, EUROSTAR, and other studies would
take issue with that comment.2-5 Nonetheless, I think Hiramoto et
al are pointing out that a large single-center study can bring a
unique perspective when it combines consistency in evaluation and
follow-up with access to the patient’s chart and raw imaging data.
Of course, this unique perspective can lead to bias, but it can also
provide unique insights.
Most of the insights in this paper have a sound basis in fact, as
well as some controversy: (1) The Zenith device has very good
mid-term results, consistent with EUROSTAR, clinical trials, and
other studies. I will avoid discussing the “barbs” regarding other
devices, as this is not a concurrent comparative study including
other devices. (2) Opinions regarding intervention for type II
endoleak are changing. I would like to have seen more information
about how often the treatment of endoleak was successful in
stopping the endoleak or resolving aneurysm enlargement, as this
would have helped influence decision-making regarding follow-up
and intervention. (3) When a device has a low rate of failures and
reinterventions, any imagingmodality will have a low yield. Even at
an intervention rate of 8.5% over an average 2.3 years’ follow-up,authors make a good point that if there is no endoleak on initial
computed tomography, if there is no migration of components,
and if the aneurysm is shrinking, no contrast should be needed on
future computed tomography for a device with this track record.
Noncontrast computed tomography provides good information
about migration, deformation, aneurysm sac size, and, in some
cases, fracture (the only missing parameter is endoleak). This
article should not be used as an excuse to avoid imaging studies,
nor do the authors suggest that.
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